A B S T R A C T Human plasma kallikrein is inactivated by plasma protease inhibitors. This study was designed to determine the nature of these protease inhibitors and to assess their relative importance in the inactivation of kallikrein. Therefore, the kinetics of kallikrein inactivation and the formation of kallikrein inhibitor complexes were studied in normal plasma and in plasma depleted of either a2-macroglobulin (a2M), CI inhibitor, or antithrombin (AT 1II). Prekallikrein was activated by incubation of plasma with dextran sulfate at 40C. After maximal activation, kallikrein was inactivated at 370C. Inhibition of kallikrein amidolytic activity in AT III-deficient plasma closely paralleled the inactivation rate of kallikrein in normal plasma. The inactivation rate of kallikrein in a2M-deficient plasma was slightly decreased compared with normal plasma, but in contrast to normal, CI inhibitordeficient, and AT III-deficient plasma, no kallikrein amidolytic activity remained after inactivation that was resistant to inhibition by soybean trypsin inhibitor. Suppression of kallikrein activity in CI inhibitor-deficient plasma was markedly decreased, and this was even more pronounced in plasma deficient in both CI inhibitor and a2M. The pseudo first-order rate constants for kallikrein inactivation in normal, AT Ill-deficient, a2M-deficient, CI inhibitor-deficient plasma, and plasma deficient in both a2M and CI inhibitor, were 0.68, 0.60, 0.43, 0.07, and 0.016 min-', respectively. Sodium dodecyl sulfate gradient polyacrylamide slab gel electrophoresis showed that during inactivation of kallikrein in plasma, high-Mr complexes were formed with Mr at 400,000-1,000,000, 185,000, and 125,000-135,000, which were identified as complexes of '251-kallikrein with a2M, CI inhibitor, and AT III, respectively. In addition, the presence of an unidentified kallikrein-inhibitor complex was observed in AT III-deficient plasma. 52% of the '251-kallikrein was associated with Cl-inhibitor, 35% with a2M, and Address all correspondence to Dr. van der Graaf. Received for publication 25 June 1982 
INTRODUCTION
Plasma contains several protease inhibitors that are able to inactivate proteolytic enzymes. These plasma proteins regulate and modulate the involvement of several interrelated enzyme systems in various hemostatic and inflammatory reactions.
Plasma kallikrein, a serine protease, participates in these reactions. It releases bradykinin from kininogen (1) , which increases the permeability of blood vessels, and mimics some features of the inflammatory response (2, 3) . Kallikrein is also important in the contact phase mechanisms of the intrinsic blood clotting cascade and in the generation of fibrinolytic activity (4) (5) (6) (7) (8) .
Five plasma proteinase inhibitors with varying potencies have thus far been identified as kallikrein inactivators: C1 inhibitor, a2-macroglobulin (a2M)', antithrombin III (AT III), a1-antitrypsin, and a2-anti-plasmin (9) (10) (11) (12) (13) (14) (15) (16) (17) . CI inhibitor and a2M are suggested to be important inactivators of plasma kallikrein (9) (10) (11) (12) (13) (14) (15) . The suggestion that CI inhibitor is a major inhibitor of kallikrein in plasma was based on the observation that plasma from individuals with hereditary angioneurotic edema showed a markedly decreased inhibition toward kallikrein esterolytic and amidolytic activity compared with normal plasma (11, 14, 15) . Another study (10) indicated that a2 M also contributes a substantial part of the inactivation of kallikrein in human plasma. All these studies, however, did not show the formation of complexes between kallikrein and its inhibitors in plasma, nor was the quantitative contribution of the various inhibitors to the inactivation of kallikrein in plasma determined. The present study was designed to identify the kallikrein inhibitors, to characterize the complexes formed between kallikrein and its inhibitors in plasma, and to establish the relative importance of each inhibitor for the inactivation of kallikrein in plasma.
METHODS
Prekallikrein, Factor XII, high-M, kininogen, CI inhibitor,2 a2M,2 and AT III' were isolated from human plasma as described elsewhere (18) (19) (20) . Kallikrein was prepared from prekallikrein by incubation with #3-Factor XII. (Hageman factor fragment, HFf, the 28,000-Mr form of activated Factor XII). After activation of prekallikrein, j3-Factor XII. was removed by affinity chromatography on CNBr-activated Sepharose 4B to which immunopurified anti-Factor XII antibodies were covalently coupled as previously described (21) . In the absence of reducing agents, the kallikrein preparation gave two protein bands on sodium dodecyl sulfate (SDS) polyacrylamide (PAA) gels with M, = 80,000 and three fragments with M, = 43,000, 36,000, and 33 ,000 on reduced SDS PAA gels. The specific amidolytic activity of kallikrein was 19.3 Mmol min-' mg-' using benzoyl-Pro-Phe-Arg-p-nitroanilide (Chromozym PK, Boehringer, Mannheim, West Germany) as a substrate in a concentration of 0.166 mM in 0.1 M Tris, 0.05 M NaCl, pH 8.0 at 37°C. Radiolabeling of prekallikrein and kallikrein was performed with 1251 by using the Bolton-Hunter reagent (22) . The prekallikrein preparation retained its procoagulant activity after the radiolabeling procedure, and the specific radioactivity was 0.9 ,Ci/ ,ug. Kallikrein was radiolabeled in the presence of 1 Immunopurified antibodies were prepared by affinity chromatography of the different antisera on a column of CNBr-activated Sepharose 4B (1 g) to which either purified a2M (5 mg), CI inhibitor (2.8 mg), or AT III (4.6 mg) was covalently coupled. The antibodies were eluted with 3 M KSCN in 0.01 M sodium phosphate, 0.5 M NaCl, pH 7.4 and after dialysis against 0.1 M NaHCO3, pH 8.0, they were coupled to CNBr-activated Sepharose 4B. The immunopurified antibodies against a2M, CI inhibitor, or AT III gave one precipitation line against normal human plasma; this showed a reaction of identity with the single line obtained against purified human a2M, CI inhibitor, or AT III, respectively. a2M-or CI inhibitor-deficient plasma was prepared by immunoadsorption of a2M or CI inhibitor from Factor XIIdeficient plasma by using a column of CNBr-activated Sepharose 4B (2 g ) to which immunopurified anti-Cl inhibitor (9.4 mg) or anti-a2M (17.5 mg) antibodies were covalently coupled. 5 ml of C1 inhibitor-deficient and 4.5 ml of a2M-deficient plasma were obtained. Plasma deficient in both C1 inhibitor and a2M was prepared by immunoadsorption of a2M and C1 inhibitor, respectively, from the same Factor XII-deficient plasma. AT III-deficient plasma was prepared by immunoadsorption of AT III from normal human plasma with a column of immunopurified anti-AT III antibodies (14.6 mg) covalently coupled to 2 g of CNBr-activated Sepharose 4B. 10 ml of AT III-deficient plasma was obtained. The a2M-deficient, C1 inhibitor-deficient, and AT III-deficient plasmas, and plasma deficient in both a2M and C1 inhibitor, were completely depleted of the respective appropriate inhibitor (< 1%) as measured by Laurell rocket immunoelectrophoresis (23) . The other inhibitors that were not removed by immunoadsorption remained at normal plasma levels. Also prekallikrein and high-Mr kininogen levels were at normal plasma concentrations as was Factor XII in AT III-deficient plasma. Prekallikrein, high-Mr kininogen, and Factor XII were determined by using partial thromboplastin time assays (8 (24) . The gels were run at 150 V, 25 mA, for 18 h, using running tap water for cooling. The gels were stained for protein with Coomassie blue R-250 and subsequently dried on Whatman 3-MM paper (Whatman Inc., Paper Div., Clifton, NJ). Autoradiography of the dried slab gels was performed using Sakura x-ray film A (Konishiraku Photo Inc., Co., Ltd, Tokyo). The dried gel was cut longitudinally, sliced into sections (13 X 3 mm), and then counted for radioactivity. The Inhibition of kallikrein in normal and various inhibitordeficient plasmas. Because most protease inhibitor-deficient plasmas were prepared from Factor XII-deficient plasma, purified Factor XII was added to these plasmas to obtain a final concentration of 1 U/ml in order to obtain a normal generation of kallikrein activity induced by dextran sulfate. 382. glycerol; and incubated for 60 min at 370C. 50 Al of this mixture was subsequently applied to the same SDS 3-25% gradient PAA slab gel as the plasma samples. Electrophoresis was performed for 18 h. After autoradiography, the dried gel was sliced into sections and counted for radioactivity. The contribution of the different inhibitors to complex formation with kallikrein in plasma was determined by analysis of the gel patterns.
Analysis of the contribution of different inhibitors to kallikrein inactivation using insolubilized anti-C! inhibitor, anti-a2M, and anti-AT III antibodies. 1 ml of normal plasma was incubated with 70 Ml of dextran sulfate (1 mg/ ml) at 40C. After 7 min, 20 Ml of '25I-kallikrein (3 MCi) was added to the plasma followed by incubation at 370C for 20 min. 200 Ml of this mixture was applied to a column containing CNBr-activated Sepharose 4B (0.5 g) to which anti-C1 inhibitor (1.8 mg), anti-a2M (4.4 mg), or anti-AT III (2.9 mg) antibodies had been coupled. After washing the column with eight bed-volumes of 0.05 M sodium phosphate and 0.5 M NaCl, pH 7.0, the total content of each column was counted for bound radioactivity. The radioactivity bound was corrected for the radioactivity bound to CNBr-activated Sepharose 4B to which no antibodies were coupled. The material that did not adhere to each column was tested for the presence of kallikrein amidolytic activity and of CI inhibitor, a2M, and AT III by immunodiffusion with anti-Cl inhibitor, anti-a2M, or anti-AT III antiserum.
Kinetics of '25I-kallikrein inhibitor complex formation in normal human plasma. 15 Ml of 1251-prekallikrein (4.0 MCi) was added to 100 Ml of normal human plasma followed by activation with 7 Ml of dextran sulfate (1 mg/ml) for 20 min at 4°C. Under these conditions, all 125I-prekallikrein was converted to '251-kallikrein. This mixture was incubated at 37°C and at various times a 10-Ml aliquot was removed and added to 390 Ml of 0.07 M Tris, pH 6.8, 2% SDS, and 5% glycerol. 50 Ml of this mixture was used for analysis by SDS 3-25% gradient PAA slab gel electrophoresis. The contribution of the different inhibitors to complex formation with kallikrein was determined as described above.
Inactivation of kallikrein in high-Mr kininogen-deficient plasma. 12 M1 of kallikrein ( 20.6 Ml. After 5 min, 100 Ml of high-Mr kininogen-deficient plasma was added and mixed. 15 Ml of this mixture was removed and added to a cuvette containing 1 ml of Chromozym PK to test for kallikrein amidolytic activity. The mixture was subsequently placed at 37°C and at various times 15-Ml aliquots were tested for kallikrein amidolytic activity. The AA/min was converted to percent by comparison with the AA/min of the zero time sample removed before placing the mixture at 370C.
RESULTS
Kinetics of kallikrein inactivation in normal and inhibitor-deficient plasmas. To investigate the inactivation of kallikrein in various inhibitor-deficient plasmas, the plasmas which were prepared from Factor XII-deficient plasma were first reconstituted with purified Factor XII to normal values and then incubated with dextran sulfate at 4°C. After generation of maximum kallikrein activity, the plasmas were incubated at 37°C and the inactivation of kallikrein was followed by measurement of the kallikrein amidolytic activity at several times. A rapid decrease of total and free kallikrein amidolytic activity in normal plasma was observed (Fig. 1A) curves was plotted against the incubation time at 370C, a straight line was obtained, indicating that the inactivation of free kallikrein amidolytic activity in the various plasmas followed pseudo first-order kinetics (Fig. 2) . The slope of each line is the pseudo first-order rate constant, which for the inactivation of kallikrein in normal, AT III-deficient, a2M-deficient, CI inhibitor-deficient plasma, and plasma deficient in both a2M and CI inhibitor, was 0.68, 0.60, 0.43, 0.07, and 0.016 minm-, respectively. Addition of heparin to plasma deficient in both a2M and CI inhibitor increased the pseudo first-order rate constant eightfold to 0.13 min'. Kallikrein-inhibitor complex formation: analysis by SDS 3-25 % gradient PAA slab gel electrophoresis. To study complex formation between kallikrein and its inhibitors, 1251-kallikrein was added to normal and various inhibitor-deficient plasmas followed by inactivation at 370C. Plasma samples were then subjected to SDS 3-25% gradient PAA slab gel electrophoresis. To identify the complexes formed in plasma, l251-kallikrein was incubated simultaneously with either purified CI inhibitor, a2M, or AT III and analyzed on the same gel. After autoradiography of the gel, the contribution of the different inhibitors to the inactivation of kallikrein in the various plasmas was calculated by counting the radioactivity incorporated in the SDS-resistant '251-kallikrein-inhibitor complexes. Fig. 3 shows the autoradiogram. Approximately 45% of the radioactivity in all samples remained at Mr = 80,000, suggesting that this portion of the radiolabeled kallikrein was inactive or was released from noncovalent complexes. 55% of the radioactivity in normal plasma was associated with a number of bands:
one band with apparent Mr of 185,000; several bands in Mr range of -400,000-1,000,000; and three faint bands with an Mr of 125,000, 130,000, and 135,000 (Fig. 3A) . The complexes with Mr = 400,000-1,000,000 probably resulted from complex formation between a2M and 1251-kallikrein, because purified a2M and '251-kallikrein formed apparently identical complexes (Fig. 3C ), whereas these bands were not present in a2M-deficient plasma (Fig. 3B ). The band with Mr= 185,000 in normal plasma corresponded to the complex formed between 1251-kallikrein and purified CI inhibitor (Fig. 3E) between kallikrein and CI inhibitor. Further evidence for this is obtained from the fact that this band was absent in CI inhibitor-deficient plasma (Fig. 3D) . The three faint bands with Mr = 125,000, 130,000, and 135,000 seen in normal plasma were apparently identical to those seen when '251-kallikrein formed complexes with purified At III (Fig. 3H) . These bands were the only kallikrein-inhibitor complexes seen in plasma deficient in both a2M and CI inhibitor (Fig.  SF) . However, when '25I-kallikrein was inactivated in AT III-deficient plasma, the same three bands were apparently formed. As no AT III antigen was detectable in this plasma (<1%), this suggests that during inactivation of kallikrein in plasma, complexes with Mr = 125,000-135,000 are formed between kallikrein and an inhibitor other than AT III. Table I Complex formation between kallikrein and each inhibitor was analyzed at different times by SDS gradient PAA slab gel electrophoresis and plotted as percent radioactivity present in a kallikrein-inhibitor complex of the radioactivity associated with all kallikrein-inhibitor complexes at 20 mmn at 370(2* 154 F. van der Graaf, J. A. Koedam, and B. N. Bouma at 370C, a2M immediately formed complexes with kallikrein. At the first time point (t = 20 s), more kallikrein was bound to a2M than to CI inhibitor. However, between ½/2 and 2 min, complex formation between kallikrein and CI inhibitor increased at a higher rate than complex formation between a2M and kallikrein. During this time period, the rate of inactivation of kallikrein was relatively fast (Fig. 1A) . (Fig. 5 ). For this experiment, high-Mr kininogen-deficient plasma was used from two unrelated congenitally high-Mr kininogendeficient patients. The same results were obtained with both plasmas, indicating that high-Mr kininogen does not protect kallikrein from inactivation in plasma. DISCUSSION The relative importance of plasma protease inhibitors in the inhibition of kallikrein in plasma was studied as well as the structure and nature of the interaction between kallikrein and its inhibitors during inactivation in plasma. Therefore, the kinetics of inactivation of kallikrein in protease inhibitor-depleted plasmas was investigated. Because plasma deficient in AT III or a2M was not available, artificially depleted plasmas were used in our study. a2M, C1 inhibitor, AT III, or both a2M and C1 inhibitor were removed by immunoadsorption by using insolubilized immunopurified anti-inhibitor antibodies. Factor XII-deficient plasma (Fig. 1) . This remaining activity is not inhibitable by SBTI, a plant inhibitor that rapidly inactivates the activity of kallikrein. Harpel (10) showed that kallikrein esterolytic activity present in plasma after 5 min incubation at 370C in the presence of kaolin was only partly inhibitable by SBTI. Experiments performed with purified components indicated that kallikrein binds to a2M while retaining part of its esterolytic or amidolytic activity2 (10, 26) . Therefore, it is likely that the remaining kallikrein amidolytic activity seen in normal, C1 inhibitor-deficient, and AT III-deficient plasma is caused by a2M-bound kallikrein. Further evidence is obtained from the fact that this remaining activity is not present in a2M-deficient plasma. The absence of C1 inhibitor results in a markedly decreased rate of kallikrein inactivation and a 90% reduction in the pseudo first-order rate constant, whereas the rate constant is reduced to 63% in the absence of a2M. The importance of these inhibitors can be demonstrated when both C1 inhibitor and a2M are absent. The pseudo first-order rate constant is then reduced to 2% of that in normal plasma. The absence of AT III in plasma appears to have a minor influence on the rate of kallikrein inactivation. However, when heparin is added to plasma deficient in both a2M and CI inhibitor, the inactivation rate constant for free kallikrein amidolytic activity increases approximately eight times, which suggests that AT III can play a role in the inactivation of kallikrein in plasma in the presence of heparin. This is also illustrated by the fact that addition of heparin to plasma from patients with hereditary angioneurotic edema was shown to increase the kallikrein inhibitory capacity of this plasma (27) . Our observations indicate that CI inhibitor is responsible for the relatively rapid rate of kallikrein inactivation in plasma, whereas of all other protease inhibitors, only a2M appears to play a major role. These results agree with other reports that suggested that CI inhibitor and a2M are important inactivators of plasma kallikrein (9-15, 25, 26, 28) .
In plasma, kallikrein forms a number of complexes with apparent molecular weights in the range of 400,000-1,000,000, 185,000, and 125,000-135,000. By using purified proteins and plasmas depleted of inhibitors, the complexes were identified. The complexes with molecular weights in the range of 400,000-1,000,000 were due to the formation of complexes between a2M and kallikrein; the complex at M, = 185,000 was the CI inhibitor-kallikrein complex.
The complexes at M, = 125,000, 130,000, and 135,000 might be due to complex formation between kallikrein and AT III, because identical complexes were formed between purified kallikrein and AT III. Vennerod (28) reported kinetic studies of kallikrein inactivation in plasma. The contribution of CI inhibitor and a2M to kallikrein inactivation in undiluted plasma was calculated to be 58 and 38%, respectively, which agrees with the results obtained in this study.
When the formation of complexes of kallikrein with the inhibitors was followed in the time during inactivation of kallikrein in plasma at 37°C, the C1 inhibitor-kallikrein complex was formed at a higher rate than the a2M-kallikrein complex. But a2M immediately formed complexes, whereas C1 inhibitor showed a sigmoidal increase of complex formation. This might be an effect of temperature, as C1 inhibitor is probably more sensitive to low temperature than is a2M. Maximum complex formation was observed after 5-6 min, correlating well with maximum kallikrein inhibition (Fig. lA) .
When using purified proteins it was reported that high-Mr kininogen reduced the rate of kallikrein inactivation by C1 inhibitor (25) , a2M, AT III, and alantitrypsin (26) as a result of complex formation between kallikrein and high-Mr kininogen. Analysis of the kinetic data yielded a dissociation constant of 0.75 ,IM for this complex. Because high-Mr kininogen circulates in plasma complexed to prekallikrein (31) or kallikrein (18) , this observation might imply that highMr kininogen also influences the rate of kallikrein inactivation by its inhibitors in plasma. Therefore, we studied the inactivation rate of kallikrein in high-Mr kininogen-deficient plasma. Addition of high-Mr kininogen to this plasma (final concentration 0.53 or 1.06 ,uM) appeared to have no effect on the rate of kallikrein inactivation. Laurell rocket immunoelectrophoresis using anti-prekallikrein antibodies showed that highMr kininogen formed a complex with kallikrein under these conditions. Therefore, it seems unlikely that high-Mr kininogen plays a protective role in relation to kallikrein inactivation in plasma.
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